438 related articles for article (PubMed ID: 31881361)
1. Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.
Du K; Chitneni SK; Suzuki A; Wang Y; Henao R; Hyun J; Premont RT; Naggie S; Moylan CA; Bashir MR; Abdelmalek MF; Diehl AM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):1-21. PubMed ID: 31881361
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells.
Du K; Hyun J; Premont RT; Choi SS; Michelotti GA; Swiderska-Syn M; Dalton GD; Thelen E; Rizi BS; Jung Y; Diehl AM
Gastroenterology; 2018 Apr; 154(5):1465-1479.e13. PubMed ID: 29305935
[TBL] [Abstract][Full Text] [Related]
3. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-2α promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells.
Yan R; Cai H; Zhou X; Bao G; Bai Z; Ge RL
Front Endocrinol (Lausanne); 2024; 15():1344971. PubMed ID: 38501098
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
6. Emodin promotes hepatic stellate cell senescence and alleviates liver fibrosis via a nuclear receptor (Nur77)-mediated epigenetic regulation of glutaminase 1.
Chen L; Liang B; Xia S; Wang F; Li Z; Shao J; Zhang Z; Chen A; Zheng S; Zhang F
Br J Pharmacol; 2023 Oct; 180(19):2577-2598. PubMed ID: 37263753
[TBL] [Abstract][Full Text] [Related]
7. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
8. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
10. LncRNA SNHG11 reprograms glutaminolysis in hepatic stellate cells via Wnt/β-catenin/GLS axis.
Ying K; Zeng Y; Xu J; Wu X; Ying H; Cai W; Zhou R; Xu Q; Zhang X; Yu F
Biochem Pharmacol; 2024 Mar; 221():116044. PubMed ID: 38336157
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.
Simon J; Nuñez-García M; Fernández-Tussy P; Barbier-Torres L; Fernández-Ramos D; Gómez-Santos B; Buqué X; Lopitz-Otsoa F; Goikoetxea-Usandizaga N; Serrano-Macia M; Rodriguez-Agudo R; Bizkarguenaga M; Zubiete-Franco I; Gutiérrez-de Juan V; Cabrera D; Alonso C; Iruzubieta P; Romero-Gomez M; van Liempd S; Castro A; Nogueiras R; Varela-Rey M; Falcón-Pérez JM; Villa E; Crespo J; Lu SC; Mato JM; Aspichueta P; Delgado TC; Martínez-Chantar ML
Cell Metab; 2020 Mar; 31(3):605-622.e10. PubMed ID: 32084378
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of HSCs in a Mouse Model of NASH.
Rosenthal SB; Liu X; Ganguly S; Dhar D; Pasillas MP; Ricciardelli E; Li RZ; Troutman TD; Kisseleva T; Glass CK; Brenner DA
Hepatology; 2021 Aug; 74(2):667-685. PubMed ID: 33550587
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
14. SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells.
Zhong X; Huang M; Kim HG; Zhang Y; Chowdhury K; Cai W; Saxena R; Schwabe RF; Liangpunsakul S; Dong XC
Cell Mol Gastroenterol Hepatol; 2020; 10(2):341-364. PubMed ID: 32305562
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
16. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
17. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
Allen J; Zhang J; Quickel MD; Kennett M; Patterson AD; Hankey-Giblin PA
J Proteome Res; 2018 Sep; 17(9):3268-3280. PubMed ID: 30091925
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
Coombes JD; Choi SS; Swiderska-Syn M; Manka P; Reid DT; Palma E; Briones-Orta MA; Xie G; Younis R; Kitamura N; Della Peruta M; Bitencourt S; Dollé L; Oo YH; Mi Z; Kuo PC; Williams R; Chokshi S; Canbay A; Claridge LC; Eksteen B; Diehl AM; Syn WK
Biochim Biophys Acta; 2016 Jan; 1862(1):135-44. PubMed ID: 26529285
[TBL] [Abstract][Full Text] [Related]
19. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
20. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.
Syn WK; Agboola KM; Swiderska M; Michelotti GA; Liaskou E; Pang H; Xie G; Philips G; Chan IS; Karaca GF; Pereira Tde A; Chen Y; Mi Z; Kuo PC; Choi SS; Guy CD; Abdelmalek MF; Diehl AM
Gut; 2012 Sep; 61(9):1323-9. PubMed ID: 22427237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
